Basic Principles in Oncology Course

Chairs: A. Eniu, CH – F.A. Peccatori, IT

ESO is proposing a new comprehensive course for oncology trainees in Europe intended to bridge the gap in education between courses for students and ESO’s well-known Masterclasses. The course aims to provide orientation to the guiding principles of multidisciplinary oncological management and life as a modern oncologist.

Although some of the principles underlying oncology practice are similar to those in other branches of medicine, sub-specialisation has reduced the exposure of medical students and junior residents to oncological concepts and practice. New oncology trainees face a number of specific challenges. These include navigation of an extensive curriculum with no clear starting point, a rapidly evolving clinical landscape, and increasing clinical demands. During training, residents must also strategically plan their careers, manage any academic focus, and maintain a healthy work-life balance.

Learning Outcomes

• Update on basic principles in etiology and epidemiology
• Update on basic cancer genetics, staging and imaging
• Update on basic surgical oncology and pathology
• Update on basic radiology and chemotherapy
• Intro to paediatric oncology
• Intro to tumour board and patient issues: communication, supportive and palliative care
• Intro to clinical trials and paper appraisal

OFFICIAL LANGUAGE

The official language will be English. No translation will be available.

CME ACCREDITATION

The Basic Principles of Oncology Course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

It has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 20 European CME credits (ECMEC®s).

Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.eu

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

PARTICIPATION

Attendance is limited to 80 participants and admittance is by competitive application only. Priority will be given to applicants who have attended an ESO-ESMO course for medical students or the ESO-ESSO-ESTRO course for medical students.

Successful applicants are granted free registration.
Accommodation at the course venue for arrival on Thursday 27 October and departure on Sunday 30 October will be provided to participants not residing in the Ljubljana area.

ORGANISING SECRETARIAT

Dolores Knupfer
European School of Oncology (ESO)
Piazza Indipendenza 2
6500 Bellinzona
ph +41 91 820 09 52
e-mail: dknupfer@eso.net

In partnership with	Endorsed by

Ideal candidate:

• 1-3 years oncology training

Interested candidates should apply online providing:

• CV (template provided) with the list of publications (if the list of publication is not provided, it will be assumed that no articles have been published)
• Motivation letter
• Support letter from mentor or head of department

APPLICATION CLOSED

Matti Aapro, Clinique de Genolier, Genolier Cancer Center, Genolier, CH
Claudia Allemani, London School of Hygiene and Tropical Medicine, Department of Non-Communicable Disease Epidemiology, London, UK
Rodica Anghel, Institute of Oncology "Prof. Dr. Al Trestioreanu", -, Bucharest, RO
Assma Ben Aissa, Geneva University Hospital, Oncology Department, Geneva, CH
Stefan Bielack, Klinikum Stuttgart - Olgahospital, Dept. of Pediatric Oncology, Hematology, Immunology Dpt., Stuttgart, DE
Snezana Bosnjak, Institute of Oncology and Radiology of Serbia, Supportive Oncology & Palliative Care Dpt., Belgrade, RS
Jasna But Hadžic, University of Ljubljana, Oncology and Radiotherapy Dept., Ljubljana, SI
Franco Cavalli, Oncology Institute of Southern Switzerland, Ufficio Prof. Cavalli, Bellinzona, CH
Tanja Cufer, University of Ljubljana, Medical Faculty, Ljubljana, SI
Giuseppe Curigliano, European Institute of Oncology / University of Milan, New Drugs for Innovative Therapies Division, Milano, IT
Filippo De Braud, University of Milan, Milan, IT
Alexandru Eniu, Riviera-Chablais Hospital, Interdisciplinary Oncology Service, Rennaz, CH
Laurentia Nicoleta Gales, Institutul Oncologic „Prof. Dr. Alexandru Trestioreanu", Oncology Dept., Bucharest, RO
Douglas Hanahan, ISREC- Swiss Institute for Experimental Cancer, School of Life Sciences, Lausanne, CH
Matteo Lambertini, Policlinico San Martino Hospital – University of Genoa, Medical Oncology Department, U.O.C. Clinica di Oncologia Medica, Genoa, IT
Erika Matos, Institute of Oncology Ljubljana, Dept. of Medical Oncology, Ljubljana, SI
Olivia Pagani, Riviera-Chablais Hospital, Interdisciplinary Oncology Service, Rennaz, CH
Fedro Alessandro Peccatori, European Institute of Oncology, Dept. of Fertility and Procreation in Oncology, Milano, IT
Giancarlo Pruneri, National Cancer Institute, IRCCS Foundation, Pathology Dpt., Milano, IT
Isabel T. Rubio, Clínica Universidad de Navarra, Breast Surgical Oncology Dpt., Madrid, ES
Florian Scotté, Institute Gustave Roussy, Medical Oncology and supportive care department, Villejuif, FR
Bostjan Seruga, Institute of Oncology Ljubljana, Dept. of Medical Oncology, Ljubljana, SI
Petra Steyerova, General University Hospital Prague, Clinic of Radiology, Breast Cancer screening and diagnostic center, Prague 2, CZ
Primoz Strojan, Institute of Oncology, Dept.of Radiation Oncology, Ljubljana, SI
Ian Tannock, Princess Margaret Hospital, Dept. of Oncology and Hematology, Toronto, CA
Luzia Travado, Champalimaud Foundation, Champalimaud Centre For the Unknown, Lisbon, PT
Sheila Unger, University Hospital Centre Vaudois, Genetic Medicine Department, Lausanne, CH
Janez Zgajnar, Institute of Oncology Ljubljana, Dept. of Surgical Oncology, Ljubljana, SI